Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shaw

Showing results (581-590 of 742) with videos related to

Pageof 75
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
ACS Catalysis|January 11, 2024
Deconvoluting Nonlinear Catalyst-Substrate Effects in the Intramolecular Dirhodium-Catalyzed C-H Insertion of Donor/Donor Carbenes Using Data Science ToolsLucas W Souza, Beck R Miller, Ryan C Cammarota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancerJulian Huang, Mihaela Aldea, Kathryn W Miller, et al.
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Pageof 75

Showing results (581-590 of 742) with videos related to

Sort By:
Pageof 75
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
ACS Catalysis|January 11, 2024
Deconvoluting Nonlinear Catalyst-Substrate Effects in the Intramolecular Dirhodium-Catalyzed C-H Insertion of Donor/Donor Carbenes Using Data Science ToolsLucas W Souza, Beck R Miller, Ryan C Cammarota, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancerJulian Huang, Mihaela Aldea, Kathryn W Miller, et al.
Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Pageof 75